Simulations Plus

Simulations Plus P/FCF

The P/FCF (Price-to-Free-Cash-Flow Ratio) of Simulations Plus (SLP) as of Oct 3, 2026 is 14.22. In the previous year, P/FCF (Price-to-Free-Cash-Flow Ratio) was 19.41 — a change of -26.76% (lower).

P/FCF

14.22

YoY

-26.76%

Last updated:

P/FCF (Price-to-Free-Cash-Flow Ratio) of Simulations Plus is 2026 14.22 . P/FCF (Price-to-Free-Cash-Flow Ratio) of Simulations Plus was 2025 19.41 . It decreases by -26.76% lower compared to the previous year.

The Simulations Plus P/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/FCF
Date
P/FCF
Jan 1, 2018
35.58 USD
Jan 1, 2019
25.57 USD
Jan 1, 2020
29.73 USD
Jan 1, 2021
16.93 USD
Jan 1, 2022
17.77 USD
Jan 1, 2023
14.08 USD
Jan 1, 2024
19.41 USD
Jan 1, 2025
14.22 USD
The Simulations Plus P/FCF history
YEARP/FCFYoY
14.22-26.76%
19.41+37.86%
14.08-20.78%
17.77+5.00%
16.93-43.07%
29.73+16.28%
25.57-28.13%
35.58-23.57%
46.56-21.40%
59.23+41.01%
42.00-76.04%
175.28—
Access this data via the Eulerpool API

Simulations Plus Stock analysis

What does Simulations Plus do? Simulations Plus Inc is a company that offers software and services for the pharmaceutical industry. The company was founded in 1996 by Dr. Walt Woltosz and is headquartered in Lancaster, California. Simulations Plus began with the development of GastroPlus, a software that simulates the effects of drugs in the body using mathematical models. This software quickly became an important tool for the pharmaceutical industry to improve the effectiveness and safety of medications. Simulations Plus's business model is based on providing high-quality software and services for the pharmaceutical industry. They offer a wide range of products aimed at improving the effectiveness and safety of drugs by optimizing drug development and design. These products include software for simulating and analyzing the pharmacokinetics and dynamics of medications, a model for detecting and avoiding potential life-threatening liver damage, a cloud-based platform for simplifying the work of scientists and researchers, and services to assist with regulatory affairs and obtaining product approvals. Simulations Plus is known for its high-quality products and excellent customer support, and their various divisions and products contribute to improving the effectiveness and safety of medications, ultimately promoting patient health. The translation of the text is: "Simulations Plus Inc is a company that offers software and services for the pharmaceutical industry. The company was founded in 1996 by Dr. Walt Woltosz and is headquartered in Lancaster, California. Simulations Plus began with the development of GastroPlus, a software that simulates the effects of drugs in the body using mathematical models. This software quickly became an important tool for the pharmaceutical industry to improve the effectiveness and safety of medications. Simulations Plus's business model is based on providing high-quality software and services for the pharmaceutical industry. They offer a wide range of products aimed at improving the effectiveness and safety of drugs by optimizing drug development and design. These products include software for simulating and analyzing the pharmacokinetics and dynamics of medications, a model for detecting and avoiding potential life-threatening liver damage, a cloud-based platform for simplifying the work of scientists and researchers, and services to assist with regulatory affairs and obtaining product approvals. Simulations Plus is known for its high-quality products and excellent customer support, and their various divisions and products contribute to improving the effectiveness and safety of medications, ultimately promoting patient health." Simulations Plus is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Simulations Plus stock

P/FCF (Price-to-Free-Cash-Flow Ratio) of Simulations Plus is 14.22 in 2026.

P/FCF (Price-to-Free-Cash-Flow Ratio) of Simulations Plus changed from 19.41 to 14.22, representing a -26.76% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/FCF (Price-to-Free-Cash-Flow Ratio) Simulations Plus since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Free-Cash-Flow ratio measures how much investors pay for each unit of free cash flow. A lower ratio may indicate better value.

P/FCF = Market Capitalization / Free Cash Flow

To evaluate P/FCF (Price-to-Free-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/FCF (Price-to-Free-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/FCF (Price-to-Free-Cash-Flow Ratio)'s Simulations Plus with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Simulations Plus

All Key Metrics — Simulations Plus